profile: Loyola University Chicago Health Sciences Campus

Profile Image
Name: Debra Hoppensteadt-Moorman
Degree: Ph.D.
Rank: Professor
Primary Department: Department of Pathology and Laboratory Medicine

Biography

Hobbies: Cooking

Research

Publications: Allen M, Bansal V, Siddiqui F, Hoppensteadt D, Krupa E, Fareed J, Kantarcioglu B. The Relevance of Thrombo-Inflammatory Biomarkers and Their Relationship with Circulating Glycosaminoglycans in End-Stage Renal Disease Patients CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Kantarcioglu B, Darki A, Siddiqui F, Hoppensteadt D, Lewis J, Kr?mer R, Adiguzel C, Fareed J. The Relevance of Anti-PF4 Antibody Isotypes and Endogenous Glycosaminoglycans and their Relationship with Inflammatory Biomarkers in Pulmonary Embolism Patients CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Kantarcioglu B, Darki A, Siddiqui F, Krupa E, Vural M, Kacmaz M, Hoppensteadt D, Iqbal O, Jeske W, Walenga J, Adiguzel C, Fareed J. Predictive Role of Blood Cellular Indices and Their Relationship with Endogenous Glycosaminoglycans as Determinants of Inflammatory Biomarkers in Pulmonary Embolism CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; DeVon HA, Uwizeye G, Cai HY, Shroff AR, Briller JE, Ardati A, Hoppensteadt D, Rountree L, Schlaeger JM. Feasibility and preliminary efficacy of acupuncture for angina in an underserved diverse population Medical Acupuncture ;; Darwish I, Fareed J, Brailovsky Y, Hoppensteadt D, Slajus B, Bontekoe E, De Stefano F, Reed T, Darki A. Dysregulation of Biomarkers of Hemostatic Activation and Inflammatory Processes are Associated with Adverse Outcomes in Pulmonary Embolism CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Costa R, Fatourou E, Hoppensteadt D, Fareed J, Halaris A. Cardiolipin Antibody: A Potential Biomarker for Depression PERSONALIZED MEDICINE ;; Goldstein J, Dieter RS, Bansal V, Wieschhaus K, Dieter RS 2nd, Bontekoe E, Hoppensteadt D, Fareed J. Arterial-renal Syndrome in Patients with ESRD, a New Disease Paradigm CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Bontekoe E, Brailovsky Y, Hoppensteadt D, Bontekoe J, Siddiqui F, Newman J, Iqbal O, Reed T, Fareed J, Darki A. Upregulation of Inflammatory Cytokines in Pulmonary Embolism Using Biochip-Array Profiling CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Sadek M, Iqbal O, Siddiqui F, Till S, Mazariegos M, Campbell E, Mudaliar K, Speiser J, Bontekoe E, Kouta A, Farooqui A, Daravath B, Qneibi D, Sadek R, Hoppensteadt D, Fareed J, Bouchard C. The Role of IL-13, IL-15 and Granulysin in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Khanna R, Slovacek H, Liles J, Haddad S, Poredos P, Bontekoe E, Jezovnik M, Hoppensteadt D, Fareed J, Hopkinson W. Regulation of Cortisol in Patients Undergoing Total Joint Arthoplasty CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Wegrzyn G, Walborn A, Rondina M, Fareed J, Hoppensteadt D. Biomarkers of Platelet Activation and Their Prognostic Value in Patients With Sepsis-Associated Disseminated Intravascular Coagulopathy CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Nichols JH, Brandler ES, Fantz CR, Fisher K, Goodman MD, Headden G, Hoppensteadt D, Matika R, Peacock WF, Rodrigo J, Sch?tzenmeister A, Swanson JR, Canada-Vilalta C, Miles G, Tran N. A Multicenter Evaluation of a Point-of-Care Blood Glucose Meter System in Critically Ill Patients The Journal of Applied Laboratory Medicine ;; Castillo MFR, Cohen A, Edberg D, Hoppensteadt D, Fareed J, Martin B, Halaris A. Vascular endothelial growth factor in bipolar depression: A potential biomarker for diagnosis and treatment outcome prediction Psychiatry research ;; Siddiqui F, Antic D, Tafur A, Bontekoe E, Hoppensteadt D, Gerotziafas G, Elalamy I, Fareed J. Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Kouta A, Hoppensteadt D, Bontekoe E, Jeske W, Duff R, Cera L, Fareed J. Studies on Tissue Factor Pathway Inhibitor Antigen Release by Bovine, Ovine and Porcine Heparins Following Intravenous Administration to Non-Human Primates CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Patel D, Druck A, Hoppensteadt D, Bansal V, Brailovsky Y, Syed M, Fareed J. Relationship Between 25-Hydroxyvitamin D, Renin, and Collagen Remodeling Biomarkers in Atrial Fibrillation CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Bontekoe J, Bansal V, Lee J, Syed M, Hoppensteadt D, Maia P, Walborn A, Liles J, Vasaiwala S, Fareed J. Procalcitonin as a Marker of Comorbid Atrial Fibrillation in Chronic Kidney Disease and History of Sepsis CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Edberg D, Hoppensteadt D, Walborn A, Fareed J, Sinacore J, Halaris A. Plasma MCP-1 levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment Journal of psychiatric research ;; Phan T, Brailovsky Y, Fareed J, Hoppensteadt D, Iqbal O, Darki A. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios Predict All-Cause Mortality in Acute Pulmonary Embolism CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Murata S, Murphy M, Hoppensteadt D, Fareed J, Welborn A, Halaris A. Effects of adjunctive inflammatory modulation on IL-1? in treatment resistant bipolar depression Brain, Behavior, & Immunity ;; Levi M, Vincent JL, Tanaka K, Radford AH, Kayanoki T, Fineberg DA, Hoppensteadt D, Fareed J. Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy Critical care medicine ;; Walborn A, Rondina M, Fareed J, Hoppensteadt D. Development of an Algorithm to Predict Mortality in Patients With Sepsis and Coagulopathy CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Siddiqui F, Hoppensteadt D, Bontekoe E, Farooqui A, Jeske W, Fareed J. Comparative Anticoagulant and Thrombin Generation Inhibitory Profile of Heparin, Sulodexide and Its Components CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Siddiqui F, Tafur A, Bontekoe E, Iqbal O, Jeske W, Mehrotra S, Hoppensteadt D, Ramacciotti E, Fareed J. Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Siddiqui F, Tafur A, Ramacciotti LS, Jeske W, Hoppensteadt D, Ramacciotti E, Iqbal O, Fareed J. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Druck A, Patel D, Bansal V, Hoppensteadt D, Fareed J. Osteopontin Levels in Patients With Chronic Kidney Disease Stage 5 on Hemodialysis Directly Correlate With Intact Parathyroid Hormone and Alkaline Phosphatase CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Thorson C, Galicia K, Burleson A, Bouchard O, Hoppensteadt D, Fareed J, Hopkinson W. Matrix Metalloproteinases and Their Inhibitors and Proteoglycan 4 in Patients Undergoing Total Joint Arthroplasty CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Patel P, Walborn A, Rondina M, Fareed J, Hoppensteadt D. Markers of Inflammation and Infection in Sepsis and Disseminated Intravascular Coagulation CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Siddiqui F, Hoppensteadt D, Jeske W, Iqbal O, Tafur A, Fareed J. Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Walborn A, Rondina M, Mosier M, Fareed J, Hoppensteadt D. Endothelial Dysfunction Is Associated with Mortality and Severity of Coagulopathy in Patients with Sepsis and Disseminated Intravascular Coagulation CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Chen J, Yu Y, Fareed J, Hoppensteadt D, Jeske W, Kouta A, Jin C, Jin Y, Yao Y, Xia K, Zhang F, Chen S, Ye X, Linhardt RJ. Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Kouta A, Jeske W, Hoppensteadt D, Iqbal O, Yao Y, Fareed J. Comparative Pharmacological Profiles of Various Bovine, Ovine, and Porcine Heparins CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Ouyang Y, Han X, Yu Y, Chen J, Fu L, Zhang F, Linhardt RJ, Fareed J, Hoppensteadt D, Jeske W, Kouta A, Zhang Z, Xia K. Chemometric analysis of porcine, bovine and ovine heparins Journal of pharmaceutical and biomedical analysis ;; Jeske W, Kouta A, Farooqui A, Siddiqui F, Rangnekar V, Niverthi M, Laddu R, Hoppensteadt D, Iqbal O, Walenga J, Fareed J. Bovine Mucosal Heparins Are Comparable to Porcine Mucosal Heparin at USP Potency Adjusted Levels Frontiers in medicine ;; Schlaeger J, Cai HY, Steffen AD, Angulo V, Shroff AR, Briller JE, Hoppensteadt D, Uwizeye G, Pauls HA, Takayama M, Yajima H, Takakura N, DeVon HA. Acupuncture to Improve Symptoms for Stable Angina: Protocol for a Randomized Controlled Trial JMIR research protocols ;; Shih L, Guler N, Syed D, Hopkinson W, McComas KN, Walborn A, Hoppensteadt D, Fareed J, Rondina MT. Postoperative Changes in the Systemic Inflammatory Milieu in Older Surgical Patients CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Lattimer CR, Fareed J, Hoppensteadt D, Maia P, Ligi D, Mannello F, Kalodiki E. Validation of a Gravitational Model to Study Local Endogenous Biomarkers in Chronic Venous Insufficiency EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY ;; Dansdill D, Halandras PM, Beverly J, Jeske W, Hoppensteadt D, Emanuele M, Fareed J, Cho JS. Synthetic, organic compound vepoloxamer (P-188) potentiates tissue plasminogen activator Journal of Vascular Surgery ;; Edberg D, Hoppensteadt D, Walborn A, Fareed J, Sinacore J, Halaris A. Plasma C-reactive protein levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment Journal of psychiatric research ;; Tanaka K, Tawara S, Tsuruta K, Hoppensteadt D, Fareed J. Pharmacological Differentiation of Thrombomodulin Alfa and Activated Protein C on Coagulation and Fibrinolysis In Vitro CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Wanderling C, Liles J, Davis E, Schmitt D, Statz S, Guler N, Hoppensteadt D, Fareed J, Hopkinson W. Levels of Matrix-Degrading Enzymes and Lubricin in Patients With Degenerative Joint Disease Requiring Arthroplasty CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Walborn A, Williams M, Fareed J, Hoppensteadt D. International Normalized Ratio Relevance to the Observed Coagulation Abnormalities in Warfarin Treatment and Disseminated Intravascular Coagulation CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Galicia K, Thorson C, Banos A, Rondina M, Hopkinson W, Hoppensteadt D, Fareed J. Inflammatory Biomarker Profiling in Total Joint Arthroplasty and Its Relevance to Circulating Levels of Lubricin, a Novel Proteoglycan CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; McClane N, Jeske W, Walenga JM, Escalante V, Hoppensteadt D, Schwartz J, Bakhos M. Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Otto A, Fareed J, Liles J, Statz S, Walborn A, Rowe T, Jabati S, Hoppensteadt D, Syed MA. Fibrinolytic Deficit and Platelet Activation in Atrial Fibrillation and Their Postablation Modulation CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Phan T, Mcmillan R, Skiadopoulos L, Walborn A, Hoppensteadt D, Fareed J, Bansal V. Elevated extracellular nucleosomes and their relevance to inflammation in stage 5 chronic kidney disease International Angiology ;; Papageorgiou C, Jourdi G, Adjambri E, Walborn A, Patel P, Fareed J, Elalamy I, Hoppensteadt D, Gerotziafas GT. Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Jeske W, Kouta A, Duff R, Rangnekar V, Niverthi M, Hoppensteadt D, Fareed J, Yao Y. Comparative Pharmacokinetic Profile of 3 Batches of Ovine Low-Molecular-Weight Heparin and 1 Batch of Branded Enoxaparin CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Lee J, McMillan R, Skiadopoulos L, Bansal V, Biller J, Hoppensteadt D, Fareed J. Circulating Biomarker Levels in Patients With Stage 5 Chronic Kidney Disease With Respect to Neurovascular Diseases CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Jabati S, Fareed J, Liles J, Otto A, Hoppensteadt D, Bontekoe J, Phan T, Walborn A, Syed M. Biomarkers of Inflammation, Thrombogenesis, and Collagen Turnover in Patients With Atrial Fibrillation CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; McMillan R, Skiadopoulos L, Hoppensteadt D, Guler N, Bansal V, Parasuraman R, Fareed J. Biomarkers of Endothelial, Renal, and Platelet Dysfunction in Stage 5 Chronic Kidney Disease Hemodialysis Patients With Heart Failure CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Lee J, Bontekoe J, Trac B, Bansal V, Biller J, Hoppensteadt D, Maia P, Walborn A, Fareed J. Biomarker Profiling of Neurovascular Diseases in Patients with Stage 5 Chronic Kidney Disease CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Bontekoe J, Lee J, Bansal V, Syed M, Hoppensteadt D, Maia P, Walborn A, Liles J, Brailovsky E, Fareed J. Biomarker Profiling in Stage 5 Chronic Kidney Disease Identifies the Relationship between Angiopoietin-2 and Atrial Fibrillation CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Walborn A, Hoppensteadt D, Syed D, Mosier M, Fareed J. Biomarker Profile of Sepsis-Associated Coagulopathy Using Biochip Assay for Inflammatory Cytokines CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Statz S, Sabal G, Walborn A, Williams M, Hoppensteadt D, Mosier M, Rondina M, Fareed J. Angiopoietin 2 Levels in the Risk Stratification and Mortality Outcome Prediction of Sepsis-Associated Coagulopathy CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Clark-Raymond A, Meresh E, Hoppensteadt D, Fareed J, Sinacore J, Garlenski B, Halaris A. Vascular endothelial growth factor: Potential predictor of treatment response in major depression World Journal of Biological Psychiatry ;; Guler N, Abro S, Emanuele M, Iqbal O, Hoppensteadt D, Fareed J. The Protective Effect of Poloxamer-188 on Platelet Functions CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Xu Y, Chandarajoti K, Zhang X, Pagadala V, Dou W, Hoppensteadt DM, Sparkenbaugh EM, Cooley B, Daily S, Key NS, Severynse-Stevens D, Fareed J, Linhardt RJ, Pawlinski R, Liu J. Synthetic oligosaccharides can replace animal-sourced low-molecular weight heparins Science translational medicine ;; Sadeghi N, Iacobelli M, Vaziri B, Kahn D, Hoppensteadt D, Guler N, Fareed J. Recombinant Factor VIIa-Mediated Activation of Prothrombin Complex Concentrates CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Saluk J, Banos A, Hopkinson W, Rees H, Syed D, Hoppensteadt D, Abro S, Iqbal O, Fareed J. Prevalence of metabolic syndrome in patients undergoing total joint arthroplasty and relevance of biomarkers International Angiology ;; Low C, Syed D, Khan D, Tetik S, Walborn A, Hoppensteadt D, Mosier M, Fareed J. Modulation of Interleukins in Sepsis-Associated Clotting Disorders: Interplay With Hemostatic Derangement CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Sweigert PJ, Bansal VK, Hoppensteadt DA, Saluk JL, Syed DA, Fareed J. Inflammatory and Metabolic Syndrome Biomarker Analysis of Vascular Outcomes in End-stage Renal Disease International Angiology ;; Saluk JL, Bansal VK, Hoppensteadt DA, Syed DA, Abro S, Fareed J. Effect of erythropoietin stimulating agents on vascular endothelial growth factor levels in patients with end stage renal disease International Angiology ;; Wanderling C, Liles J, Finkler E, Carlsgaard P, Hopkinson W, Guler N, Hoppensteadt D, Fareed J. Dysregulation of Tissue Factor, Thrombin-Activatable Fibrinolysis Inhibitor, and Fibrinogen in Patients Undergoing Total Joint Arthroplasty CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Liu X, St Ange K, Fareed J, Hoppensteadt D, Jeske W, Kouta A, Chi L, Jin C, Jin Y, Yao Y, Linhardt RJ. Comparison of Low-Molecular-Weight Heparins Prepared From Bovine Heparins With Enoxaparin CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Saluk J, Hoppensteadt D, Syed D, Liles J, Abro S, Walborn A, Bansal V, Fareed J. Biomarker profiling of plasma samples utilizing RANDOX biochip array technology International Angiology ;; Ramacciotti E, Hoppensteadt D, Fareed J. Betrixaban for VTE Prevention in the Medically Ill Population, the APEX Trial: Good News for This Needy Population? CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Saluk J, Bansal V, Hoppensteadt D, Syed D, Abro S, Fareed J. Prevalence of metabolic syndrome in patients with end stage renal disease and relevance of biomarkers International Angiology ;; Burleson A, Guler N, Banos A, Syed D, Wanderling C, Hoppensteadt D, Rees H, Fareed J, Hopkinson W. Perioperative Factors and Their Effect on the Fibrinolytic System in Arthroplasty Patients CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Alexander K, Banos A, Abro S, Hoppensteadt D, Fareed J, Rees H, Hopkinson W. Levels of Matrix Metalloproteinases in Arthroplasty Patients and Their Correlation With Inflammatory and Thrombotic Activation Processes CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Abro S, Clark M, Barkan G, Hoppensteadt D, Fareed J, Wojick E, Quek M. Inflammation and Hemostatic Activation may Contribute to Postsurgical Thrombosis in Patients With Bladder Cancer CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Liles J, Liles J, Wanderling C, Syed M, Hoppensteadt D, Fareed J. Increased Level of Thrombotic Biomarkers in Patients with Atrial Fibrillation Despite Traditional and New Anticoagulant Therapy CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Guler N, Burleson A, Syed D, Banos A, Hopkinson W, Hoppensteadt D, Rees H, Fareed J. Fibrinolytic Dysregulation in Total Joint Arthroplasty Patients: Potential Clinical Implications CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Lattimer CR, Kalodiki E, Geroulakos G, Hoppensteadt D, Fareed J. Endogenous pro-thrombotic biomarkers from the arm and leg may not have the same value PHLEBOLOGY ;; Lattimer CR, Kalodiki E, Geroulakos G, Hoppensteadt D, Fareed J. Are Inflammatory Biomarkers Increased in Varicose Vein Blood? CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; St Ange K, Onishi A, Fu L, Sun X, Lin L, Mori D, Zhang F, Dordick JS, Fareed J, Hoppensteadt D, Jeske W, Linhardt RJ. Analysis of Heparins Derived From Bovine Tissues and Comparison to Porcine Intestinal Heparins CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Richards J, Bansal V, Iqbal O, Hoppensteadt D, Fareed J. Immunoenzymatic and biochip array profiling of the biomarkers of inflammation and hemostatic activation processes in ESRD CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Syed D, Iqbal O, Mosier M, Mitchell R, Hoppensteadt D, Bouchard C, Fareed J, Gamelli R. Elevated endocan levels and its association with clinical severity in Stevens-Johnson Syndrome and toxic epidermal necrolysis International Angiology ;; Hoppensteadt D, Tsuruta K, Hirman J, Kaul I, Osawa Y, Fareed J. Dysregulation of inflammatory and hemostatic markers in sepsis and suspected disseminated intravascular coagulation CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Halaris A, Myint AM, Savant V, Meresh E, Lim E, Guillemin G, Hoppensteadt D, Fareed J, Sinacore J. Does escitalopram reduce neurotoxicity in major depression? Journal of psychiatric research ;; Lattimer CR, Kalodiki E, Geroulakos G, Syed D, Hoppensteadt D, Fareed J. d-Dimer Levels are Significantly Increased in Blood Taken From Varicose Veins Compared With Antecubital Blood From the Same Patient Angiology ;; Kalodiki E, Fareed J, Syed D, Geroulakos G, Hoppensteadt D, Lattimer CR. Blood Sampled Directly from Varicose Veins Reveals Activation of Inflammatory Processes Journal of vascular surgery. Venous and lymphatic disorders ;; Clark-Raymond A, Meresh E, Hoppensteadt D, Fareed J, Sinacore J, Halaris A. Vascular Endothelial Growth Factor: a potential diagnostic biomarker for major depression Journal of psychiatric research ;; Hoppensteadt D, Tsuruta K, Cunanan J, Hirman J, Kaul I, Osawa Y, Fareed J. Thrombin generation mediators and markers in sepsis-associated coagulopathy and their modulation by recombinant thrombomodulin CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; DeVon HA, Piano MR, Rosenfeld AG, Hoppensteadt DA. The association of pain with protein inflammatory biomarkers: a review of the literature Nursing research ;; Walenga JM, Kaiser PC, Prechel MM, Hoppensteadt D, Jeske WP, Misselwitz F, Bacher P, Lassen MR, Fareed J. Sustained release of tissue factor following thrombosis of lower limb trauma CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Saban KL, Hoppensteadt D, Bryant FB, DeVon HA. Social determinants and heat shock protein-70 among African American and non-Hispanic white women with atherosclerosis: a pilot study Biological research for nursing ;; Lattimer CR, Kalodiki E, Azzam M, Geroulakos G, Fareed J, Hoppensteadt D. Regional and Systemic Prothrombotic Biomarkers in Varicose Vein Patients and Healthy Controls Journal of vascular surgery. Venous and lymphatic disorders ;; Hoppensteadt DA, Fareed J. Pharmacological profile of sulodexide International Angiology ;; Dibble S, Andersen A, Lassen MR, Cunanan J, Hoppensteadt D, Fareed J. Inflammatory and procoagulant cytokine levels during pregnancy as predictors of adverse obstetrical complications CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Sadeghi N, Kahn D, Syed D, Iqbal O, Abro S, Eshraghi R, Hoppensteadt D, Fareed J. Comparative Biochemical and Functional Studies on a Branded Human Recombinant Factor VIIa and a Biosimilar Equivalent Product CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Hoppensteadt DA, Gray A, Jeske WP, Walenga JM, Fareed J. Anticoagulant and Antithrombotic Actions of AVE5026, an Enriched Anti-Xa Hemisynthetic Ultra-Low-Molecular-Weight Heparin CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Kaneva K, Bansal V, Hoppensteadt D, Cunanan J, Fareed J. Variations in the circulating heparin levels during maintenance hemodialysis in patients with end-stage renal disease CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Sadeghi N, Kahn D, Jeske W, Hoppensteadt D, Fareed J. Tissue factor-mediated activation of the prothrombin complex concentrate (PCC) is differently inhibited by dabigatran, rivaroxaban, and apixaban: potential clinical implication CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Sharain K, Hoppensteadt D, Bansal V, Singh A, Fareed J. Progressive increase of inflammatory biomarkers in chronic kidney disease and end-stage renal disease CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Govindan S, Kuster DW, Lin B, Kahn DJ, Jeske WP, Walenga JM, Leya F, Hoppensteadt D, Fareed J, Sadayappan S. Increase in cardiac myosin binding protein-C plasma levels is a sensitive and cardiac-specific biomarker of myocardial infarction American journal of cardiovascular disease ;; Walenga JM, Jeske WP, Hoppensteadt D, Cunanan J, Khan H, Escalante V, Fareed J, Bakhos M. Comparative studies on branded enoxaparin and a US generic version of enoxaparin CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Walenga JM, Prechel M, Hoppensteadt D, Escalante V, Chaudhry T, Jeske WP, Bakhos M. Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopenia CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Fareed J, Thethi I, Hoppensteadt D. Old versus new oral anticoagulants: focus on pharmacology Annual Review of Pharmacology and Toxicology ;; Gray A, Litinas E, Jeske W, Fareed J, Hoppensteadt D. Interactions of oversulfated chondroitin sulfate (OSCS) from different sources with unfractionated heparin CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Iqbal O, Sadeghi N, Bakhos F, Zhu H, Aranda C, Aziz J, Cunanan J, Hoppensteadt D, Fareed J. Gender-based differences in hemostatic responses Journal of personalized medicine ;; Sadeghi N, Zhu H, Setty SK, Cunanan J, Hoppensteadt D, Fareed J. Cross-reactivity of various thrombin products with anti-rabbit antibodies to bovine, human, and recombinant thrombin CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Jeske W, Litinas E, Khan H, Hoppensteadt D, Fareed J. A comparison of the pharmacodynamic behavior of branded and biosimilar enoxaparin in primates CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Nelson K, Thethi I, Cunanan J, Hoppensteadt D, Bajwa R, Fareed J, Bansal V. Upregulation of surrogate markers of inflammation and thrombogenesis in patients with ESRD: pathophysiologic and therapeutic implications CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Rahman S, Cichon M, Hoppensteadt D, Cunanan J, Jeske W, Thethi I, Fareed J. Upregulation of microparticles in DIC and its impact on inflammatory processes CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Davis R, Bansal V, Litinas E, Hoppensteadt D, Thethi I, Nelson K, Fareed J. Upregulation of inflammatory mediators in end-stage renal disease as measured using biochip array technology CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Ramacciotti E, Clark M, Sadeghi N, Hoppensteadt D, Thethi I, Gomes M, Fareed J. Review: contaminants in heparin: review of the literature, molecular profiling, and clinical implications CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Jeske WP, Walenga JM, Samama MM, Hoppensteadt D, Mayuga M, Fareed J. Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels Blood Coagulation & Fibrinolysis ;; Gomes M, Ramacciotti E, Hoppensteadt D, Walenga JM, Lewis B, Thethi I, Fareed J. An open label, non-randomized, prospective clinical trial evaluating the immunogenicity of branded enoxaparin versus biosimilars in healthy volunteers CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; "Jeske WP, Hoppensteadt D, Gray A, Walenga JM, Cunanan J, Myers L, Fareed J, Bayol A, Rigal H, Viskov C." A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin Thrombosis research ;; Jeske WP, Fareed J, Hoppensteadt DA, Lewis B, Walenga JM. Pharmacology of argatroban Expert Review of Hematology ;; Knesek MJ, Litinas E, Adiguzel C, Hopkinson W, Hoppensteadt D, Lassen M, Fareed J. Inflammatory biomarker profiling in elderly patients with acute hip fracture treated with heparins CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Kuziej J, Litinas E, Hoppensteadt DA, Liu D, Walenga JM, Fareed J, Jeske W. In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; He Zhu, Hoppensteadt D, Cunanan J, Fareed J. Cross-reactivity of rabbit anti-bovine thrombin IgGs with human alpha-thrombin and a recombinant version of human thrombin (Recothrom) CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; He Zhu, Hoppensteadt D, Morris M, Fareed J. Cross-reactivity of rabbit anti-bovine prothrombin/thrombin IgGs with bovine factor V/Va-related antigens CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Hoppensteadt DA, Neville B, Schultz C, Jeske W, Raake W, Fareed J. Comparative studies on the topical administration of mucopolysaccharide and heparin ointments in nonhuman primates CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Adiguzel C, Jeske WP, Hoppensteadt D, Walenga JM, Bansal V, Fareed J. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Zhu H, Hoppensteadt D, Iqbal O, Litinas E, Adiguzel C, Fareed J. Relative purity of different bovine thrombin preparations CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Zhu H, Hoppensteadt D, Wahi R, Cunanan J, Adiguzel C, Bick RL, Fareed J. Reduced immunogenic potential of membrane filtered bovine thrombin preparations for hemostatic application CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Piletz JE, Halaris A, Iqbal O, Hoppensteadt D, Fareed J, Zhu H, Sinacore J, Devane CL. Pro-inflammatory biomakers in depression: treatment with venlafaxine World Journal of Biological Psychiatry ;; Adiguzel C, Bansal V, Litinas E, Cunanan J, Iqbal O, Nelson K, Kannan M, Hoppensteadt D, Fareed J. Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Zhu H, Hoppensteadt D, Adiguzel C, Bick RL, Fareed J. Comparison of immunogenic potentials of bovine thrombin preparations CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Adiguzel C, Iqbal O, Hoppensteadt D, Jeske W, Cunanan J, Litinas E, He Zhu, Walenga JM, Fareed J. Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Walenga JM, Drenth AF, Mayuga M, Hoppensteadt DA, Prechel M, Harder S, Watanabe H, Osakabe M, Breddin HK. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Hoppensteadt DA, Walenga JM. The relationship between the antiphospholipid syndrome and heparin-induced thrombocytopenia HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA ;; Hoppensteadt DA, Jeske W, Walenga J, Fareed J. The future of anticoagulation Seminars in Respiratory & Critical Care Medicine ;; Fareed J, Hoppensteadt DA, Fareed D, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R. Survival of heparins, oral anticoagulants, and aspirin after the year 2010 Seminars in Thrombosis and Hemostasis ;; Walenga JM, Prechel M, Jeske WP, Hoppensteadt D, Maddineni J, Iqbal O, Messmore HL, Bakhos M. Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia British journal of haematology ;; Clark M, Hoppensteadt D, Walenga J, Myers L, Cunanan J, Jeske W, Adiguzel C, Iqbal O, Fareed J. Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate International Angiology ;; Hoppensteadt DA, Fabbrini N, Bick RL, Messmore HL, Adiguzel C, Fareed J. Laboratory evaluation of the antiphospholipid syndrome HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA ;; Jeske WP, Walenga JM, Hoppensteadt DA, Vandenberg C, Brubaker A, Adiguzel C, Bakhos M, Fareed J. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins Seminars in Thrombosis and Hemostasis ;; Hoppensteadt D, Fareed J, Klein AL, Jasper SE, Apperson-Hansen C, Lieber EA, Katz WE, Malouf JF, Stoddard MF, Pape LA; Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Investigators. Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation American Journal of Cardiology ;; Fareed J, Jeske W, Fareed D, Clark M, Wahi R, Adiguzel C, Hoppensteadt D. Are all low molecular weight heparins equivalent in the management of venous thromboembolism? CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Maddineni J, Hoppensteadt DA, Cornelli U, Manoni M, Fareed J. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Ma Q, Tobu M, Schultz C, Jeske W, Hoppensteadt D, Walenga J, Cornelli U, Lee J, Linhardt R, Hanin I, Fareed J. Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides Thrombosis research ;; Jeske WP, McDonald MK, Hoppensteadt DA, Bau EC, Mendes A, Dietrich CP, Walenga JM, Coyne E. Isolation and characterization of heparin from tuna skins CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Fareed J, Jeske WP, Hoppensteadt DA, Walenga JM. Update on the clinical applications of argatroban Future Cardiology ;; Maddineni J, Walenga JM, Jeske WP, Hoppensteadt DA, Fareed J, Wahi R, Bick RL. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Maddineni J, Jeske WP, Baltasar F, Cornelli U, Manoni M, Hoppensteadt DA, Fareed J. Modulatory effects of Escherichia coli capsular-derived sulfaminoheparosans and heparins on tissue factor-mediated activation of platelets: flow cytometric analysis CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Iqbal O, Tobu M, Aziz S, Gerdisch M, Da Valle M, Demir M, Hoppensteadt DA, Ahmad S, Walenga JM, Fareed J. Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization Journal of Cardiovascular Surgery ;; Fareed J, Leong W, Hoppensteadt DA, Jeske WP, Walenga J, Bick RL. Development of generic low molecular weight heparins: a perspective HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA ;; Tobu M, Ma Q, Iqbal O, Schultz C, Jeske W, Hoppensteadt DA, Fareed J. Comparative tissue factor pathway inhibitor release potential of heparins CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Walenga JM, Hoppensteadt DA. Monitoring the new antithrombotic drugs Seminars in Thrombosis and Hemostasis ;; Maddineni J, Ma Q, Hoppensteadt DA, Demir M, Manoni M, Cornelli U, Fareed J. Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Hoppensteadt DA, Willows L, Leitz H, Nicolaides A, Fareed J. Laboratory analysis of blood samples from patients treated with tinzaparin Seminars in Thrombosis and Hemostasis ;; Fareed J, Leong WL, Hoppensteadt DA, Jeske WP, Walenga J, Wahi R, Bick RL. Generic low-molecular-weight heparins: some practical considerations Seminars in Thrombosis and Hemostasis ;; Walenga JM, Jeske WP, Hoppensteadt D, Fareed J. Factor Xa inhibitors Methods in Molecular Medicine ;; Tobu M, Iqbal O, Fareed D, Chatha M, Hoppensteadt D, Bansal V, Fareed J. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Hoppensteadt DA, Fareed J, Bick RL. Epilogue. Expanded role of low-molecular-weight heparins in hematology and oncology Seminars in Thrombosis and Hemostasis ;; Fareed J, Ma Q, Florian M, Maddineni J, Iqbal O, Hoppensteadt DA, Bick RL. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis Seminars in Thrombosis and Hemostasis ;; Florian-Kujawski M, Hoppensteadt D, Maddineni J, Ziegler H, Fareed J. Differential regulation of thrombin activatable fibrinolytic inhibitor by low molecular weight heparins. Pharmacologic implications International Angiology ;; Ahmad S, Untch B, Haas S, Hoppensteadt DA, Misselwitz F, Messmore HL, Walenga JM, Fareed J. Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis MOLECULAR AND CELLULAR BIOCHEMISTRY ;; Fareed D, Iqbal O, Tobu M, Hoppensteadt DA, Fareed J. Blood levels of nitric oxide, C-reactive protein, and tumor necrosis factor-alpha are upregulated in patients with malignancy-associated hypercoagulable state: pathophysiologic implications CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Florian-Kujawski M, Hussain W, Chyna B, Kahn S, Hoppensteadt D, Leya F, Fareed J. Biomarker profiling of plasma from acute coronary syndrome patients. Application of ProteinChip Array analysis International Angiology ;; Fareed J, Hoppensteadt D, Schultz C, Ma Q, Kujawski MF, Neville B, Messmore H. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile Current pharmaceutical design ;; Tobu M, Iqbal O, Hoppensteadt D, Neville B, Messmore HL, Fareed J. Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Ma Q, Schultz C, Neville B, Jeske W, Hoppensteadt D, Cornelli U, Lee J, Lorens S, Hanin I, Fareed J. Pharmacodynamics and pharmacokinetics of C3, a heparin-derived oligosaccharide mixture, in non-human primates Thrombosis research ;; Fareed J, Hoppensteadt DA, Bick RL. Management of thrombotic and cardiovascular disorders in the new millenium CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Ahmad S, Bacher HP, Lassen MR, Hoppensteadt DA, Leitz H, Misselwitz F, Walenga JM, Fareed J. Investigations of the immunoglobulin subtype transformation of anti-heparin-platelet factor 4 antibodies during treatment with a low-molecular-weight heparin (clivarin) in orthopedic patients Archives of Pathology & Laboratory Medicine ;; Tobu M, Iqbal O, Messmore HL, Ma Q, Hoppensteadt DA, Fareed J. Influence of different anticoagulant agents on fibrinopeptide a generation CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Hoppensteadt D, Walenga JM, Fareed J, Bick RL. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA ;; Tobu M, Iqbal O, Ma Q, Schultz C, Jeske W, Hoppensteadt D, Lewis B, Fareed D, Fareed J. Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Walenga JM, Jeske WP, Hoppensteadt D, Fareed J. Factor Xa inhibitors: today and beyond Current Opinion in Investigational Drugs ;; Fareed J, Hoppensteadt D, Walenga J, Iqbal O, Ma Q, Jeske W, Sheikh T. Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice Clinical pharmacokinetics ;; Gerbutavicius R, Fareed J, Messmore HL Jr, Iqbal O, Hoppensteadt DA, Wehrmacher WH, Demir M, Piccolo P, Ahmad S, Ma Q, Griniute R. Reference intervals of the dilute tissue thromboplastin inhibition and dilute Russell's viper venom tests revisited CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Untch B, Ahmad S, Jeske WP, Messmore HL, Hoppensteadt DA, Walenga JM, Lietz H, Fareed J. Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG Thrombosis research ;; Fareed J, Hoppensteadt D, Iqbal O, Tobu M, Lewis BE. Practical issues in the development of argatroban: a perspective Pathophysiology of Haemostasis and Thrombosis ;; Ma Q, Dudas B, Daud A, Iqbal O, Hoppensteadt D, Jeske W, Cornelli U, Lee J, Lorens S, Mervis R, Hanin I, Capila I, Linhardt R, Fareed J. Molecular and biochemical profiling of a heparin-derived oligosaccharide, C3 Thrombosis research ;; Tobu M, Iqbal O, Hoppensteadt DA, Shultz C, Jeske W, Fareed J. Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Ahmad S, Haas S, Hoppensteadt DA, Lietz H, Reid U, Bender N, Messmore HL, Misselwitz F, Bacher P, Gaikwad BS, Jeske WP, Walenga JM, Fareed J. Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies Thrombosis research ;; Untch B, Ahmad S, Messmore HL, Schultz CL, Ma Q, Hoppensteadt DA, Walenga JM, Fareed J. Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies Thrombosis research ;; Walenga JM, Ahmad S, Hoppensteadt D, Iqbal O, Hursting MJ, Lewis BE. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia Thrombosis research ;; Iqbal O, Messmore H, Fareed J, Ahmad S, Hoppensteadt D, Hazar S, Tobu M, Aziz S, Wehrmacher W. Antithrombotic agents in the treatment of severe sepsis Expert opinion on emerging drugs ;; Walenga JM, Hoppensteadt D, Pifarr? R, Fox NL, Forman S, Hunninghake DB, Campeau L, Herd JA, Hoogwerf BJ, Hickey A, Probstfield JL, Terrin ML. The hemostatic effects of warfarin titration in post CABG patients in comparison to placebo treatment JOURNAL OF THROMBOSIS AND THROMBOLYSIS ;; Orcullo Santillan MK, Herring J, Hoppensteadt DA, Jeske W, Herbert JM, Fareed J. The effect of a novel glycoprotein IIb/IIIa antagonist, SR 121566A, on platelet aggregation and activation in rhesus monkeys CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Hoppensteadt DA, Fareed J, Raake P, Raake W. Endogenous release of tissue factor pathway inhibitor by topical application of an ointment containing mucopolysaccharide polysulfate to nonhuman primates Thrombosis research ;; Iqbal O, Aziz S, Hoppensteadt DA, Ahmad S, Walenga JM, Bakhos M, Fareed J. Emerging anticoagulant and thrombolytic drugs Expert opinion on emerging drugs ;; Demir M, Iqbal O, Untch B, Hoppensteadt DA, Gaikwad BS, Fareed J. Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Fareed J, Shaikh T, Hoppensteadt DA. Antithrombin and anti-Xa agents in the control of thrombogenesis International journal of pharmaceutics ;; Demir M, Iqbal O, Hoppensteadt DA, Piccolo P, Ahmad S, Schultz CL, Linhardt RJ, Fareed J. Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88) CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Demir M, Iqbal O, Dietrich CP, Hoppensteadt DA, Ahmad S, Daud AN, Fareed J. Anticoagulant and antiprotease effects of a novel heparinlike compound from shrimp (Penaeus brasiliensis) and its neutralization by heparinase I CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Iqbal O, Messmore H, Hoppensteadt D, Fareed J, Wehrmacher W. Thrombolytic drugs in acute myocardial infarction CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Amin HM, Ahmad S, Walenga JM, Hoppensteadt DA, Leitz H, Fareed J. Soluble P-selectin in human plasma: effect of anticoagulant matrix and its levels in patients with cardiovascular disorders CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Ahmad S, Yang LH, Ahsan A, Fu K, Iqbal O, Hoppensteadt DA, Lewis BE, Walenga JM, Fareed J. Pharmacokinetics of argatroban in primates: evidence on endogenous uptake International Angiology ;; Fareed J, Hoppensteadt DA, Bick RL. An update on heparins at the beginning of the new millennium Seminars in Thrombosis and Hemostasis ;; Walenga JM, Michal K, Hoppensteadt D, Wood JJ, Robinson JA, Bick RL. Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Fareed J, Hoppensteadt DA, Leya F, Lewis B, Callas D, Wolf H, Bick RL. Thrombogenesis in myocardial infarction and related syndromes: the role of molecular markers in diagnosis and management CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Ahmad S, Jeske WP, Walenga JM, Hoppensteadt DA, Wood JJ, Herbert JM, Messmore HL, Fareed J. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Fareed J, Walenga JM, Hoppensteadt DA, Jeske WP, Ahmad S, Lietz H, McKenna R, Messmore HL, Haas S. Soluble adhesion molecules in the HIT syndrome: pathophysiologic role and therapeutic modulation CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Fareed J, Walenga JM, Hoppensteadt DA, Jeske WP, Lietz H, Ahmad S, Callas D, Messmore HL, Haas S. Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulation Seminars in Thrombosis and Hemostasis ;; Fareed J, Fu K, Yang LH, Hoppensteadt DA. Pharmacokinetics of low molecular weight heparins in animal models Seminars in Thrombosis and Hemostasis ;; Hoppensteadt DA, Jeske WP, Walenga JM, Fu K, Yang LH, Ing TS, Herbert JM, Fareed J. Laboratory monitoring of pentasaccharide in a dog model of hemodialysis Thrombosis research ;; Walenga JM, Hoppensteadt D, Pifarr? R, Cressman MD, Hunninghake DB, Fox NL, Terrin ML, Probstfield JL. Hemostatic effects of 1 mg daily warfarin on post CABG patients. Post CABG Studies Investigators JOURNAL OF THROMBOSIS AND THROMBOLYSIS ;; Izban KF, Lietz HW, Hoppensteadt DA, Jeske WP, Fareed J, Bakhos M, Walenga JM. Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia Seminars in Thrombosis and Hemostasis ;; Walenga JM, Fasanella AR, Iqbal O, Hoppensteadt DA, Ahmad S, Wallis DE, Bakhos M. Coagulation laboratory testing in patients treated with argatroban Seminars in Thrombosis and Hemostasis ;; Ahmad S, Iqbal O, Ahsan A, Hoppensteadt DA, Lewis BE, Walenga JM, Fareed J. Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using high performance liquid chromatography and functional methods International Angiology ;; Fareed J, Lewis BE, Callas DD, Hoppensteadt DA, Walenga JM, Bick RL. Antithrombin agents: the new class of anticoagulant and antithrombotic drugs CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS ;; Fareed J, Callas D, Hoppensteadt DA, Lewis BE, Bick RL, Walenga JM. Antithrombin agents as anticoagulants and antithrombotics: implications in drug development SEMINARS IN HEMATOLOGY ;; Fareed J, Hoppensteadt DA, Jeske WP, Ahmad S, Bick RL. Acquired defects of fibrinolysis associated with thrombosis Seminars in Thrombosis and Hemostasis ;; Fareed J, Hoppensteadt DA, Leya F, Iqbal O, Wolf H, Bick R. Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes Clinical chemistry ;; Dries DJ, Walenga JM, Hoppensteadt D, Fareed J. Molecular markers of hemostatic activation and inflammation following major injury: effect of therapy with IFN-gamma Journal of Interferon & Cytokine Research ;; Yang LH, Hoppensteadt D, Fareed J. Modulation of vasoconstriction by clopidogrel and ticlopidine Thrombosis research ;; Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Low-molecular-weight heparins: pharmacologic profile and product differentiation American Journal of Cardiology ;; Fareed J, Hoppensteadt D, Jeske W, Clarizio R, Walenga JM. Low molecular weight heparins: are they different? CANADIAN JOURNAL OF CARDIOLOGY ;; Fareed J, Callas D, Hoppensteadt DA, Walenga JM, Bick RL. Antithrombin agents as anticoagulants and antithrombotics. Implications in drug development MEDICAL CLINICS OF NORTH AMERICA ;; Kowal-Vern A, Walenga JM, Sharp-Pucci M, Hoppensteadt D, Gamelli RL. Postburn edema and related changes in interleukin-2, leukocytes, platelet activation, endothelin-1, and C1 esterase inhibitor Journal of Burn Care & Rehabilitation ;; Fareed J, Hoppensteadt D, Jeske W, Clarizio R, Walenga JM. Low molecular weight heparins: a developmental perspective Expert opinion on investigational drugs ;; Hoppensteadt DA, Kahn S, Fareed J. Factor X values as a means to assess the extent of oral anticoagulation in patients receiving antithrombin drugs Clinical chemistry ;; Hoppensteadt DA, Jeske WP, Walenga JM, Fu K, Yang LH, Ing T, Herbert JM, Fareed J. Efficacy of pentasaccharide in a dog model of hemodialysis Thrombosis research ;; Jeske W, Fareed J, Eschenfelder V, Iqbal O, Hoppensteadt D, Ahsan A. Biochemical and pharmacologic characteristics of Reviparin, a low-molecular-mass heparin Seminars in Thrombosis and Hemostasis ;; Fareed J, Jeske W, Eschenfelder V, Iqbal O, Hoppensteadt D, Ahsan A. Preclinical studies on a low molecular weight heparin Thrombosis research ;; Hoppensteadt DA, Jeske W, Fareed J, Nicolaides AN. Physical and pharmacologic manipulation of the vascular system as measured by the release of TFPI and other mediators of antithrombotic actions International Angiology ;; Fareed J, Hoppensteadt DA. Pharmacology of the low-molecular-weight heparins Seminars in Thrombosis and Hemostasis ;; Jeske W, Hoppensteadt D, Callas D, Koza MJ, Fareed J. Pharmacological profiling of recombinant tissue factor pathway inhibitor Seminars in Thrombosis and Hemostasis ;; Yang LH, Hoppensteadt DA, Iqbal O, Fareed J. Defibrotide mediated inhibition of serotonin, endothelin-I, thromboxane, and serum induced contraction of canine femoral and pulmonary arterial rings Thrombosis research ;; Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Are the available low-molecular-weight heparin preparations the same? Seminars in Thrombosis and Hemostasis ;; Fareed J, Callas DD, Hoppensteadt D, Bermes EW Jr. Tissue factor antigen levels in various biological fluids Blood Coagulation & Fibrinolysis ;; Hoppensteadt DA, Jeske W, Fareed J, Bermes EW Jr. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin Blood Coagulation & Fibrinolysis ;; Iqbal O, Jeske W, Hoppensteadt D, Walenga JM, Fareed J. The approach of thromboelastography in the monitoring of new synthetic antithrombotic agents, GL-522 and GL-2021 Seminars in Thrombosis and Hemostasis ;; Hoppensteadt DA, Walenga JM, Fasanella A, Jeske W, Fareed J. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin Thrombosis research ;; Chamberlin JR, Lewis B, Leya F, Wallis D, Messmore H, Hoppensteadt D, Walenga JM, Moran S, Fareed J, McKiernan T. Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog CANADIAN JOURNAL OF CARDIOLOGY ;; Iqbal O, Jeske W, Hoppensteadt D, Koza M, Walenga JM, Fareed J, Moncada R. Procoagulant and anticoagulant effects of intravascular contrast media as assessed by thromboelastography Seminars in Thrombosis and Hemostasis ;; Fareed J, Jeske W, Eschenfelder V, Iqbal O, Hoppensteadt D, Ahsan A. Pharmacologic validation of the clinical effects of an optimized low-molecular-weight heparin-reviparin Seminars in Thrombosis and Hemostasis ;; Ahsan A, Jeske W, Hoppensteadt D, Lormeau JC, Wolf H, Fareed J. Molecular profiling and weight determination of heparins and depolymerized heparins Journal of Pharmaceutical Sciences ;; Jeske W, Hoppensteadt D, Fareed J, Bermes E. Measurement of functional and immunologic levels of tissue factor pathway inhibitor. Some methodologic considerations Blood Coagulation & Fibrinolysis ;; Fareed J, Hoppensteadt D, Iyer L, Koza M, Walenga JM, Bermes E Jr. Impact of biotechnology in the diagnostic and therapeutic management of cardiovascular disorders Advances in Experimental Medicine & Biology ;; Lojewski B, Bacher P, Iqbal O, Walenga JM, Hoppensteadt D, Leya F, Fareed J. Evaluation of hemostatic and fibrinolytic alterations associated with daily administration of low-molecular-weight heparin for a 12-week period Seminars in Thrombosis and Hemostasis ;; Jeske W, Hoppensteadt D, Klauser R, Kammereit A, Eckenberger P, Haas S, Wyld P, Fareed J. Effect of repeated Aprosulate and Enoxaparin administration on tissue factor pathway inhibitor antigen levels Blood Coagulation & Fibrinolysis ;; Hoppensteadt DA, Fasanella A, Fareed J. Effect of protamine on heparin releasable TFPI antigen levels in normal volunteers Thrombosis research ;; Callas DD, Hoppensteadt D, Fareed J. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin Seminars in Thrombosis and Hemostasis ;; Jeske W, Lormeau JC, Callas D, Iqbal O, Hoppensteadt D, Fareed J. Antithrombin III affinity dependence on the anticoagulant, antiprotease, and tissue factor pathway inhibitor actions of heparins Seminars in Thrombosis and Hemostasis ;; Kijowski R, Hoppensteadt D, Walenga J, Borris L, Lassen MR, Fareed J. Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxis in patients treated with low molecular weight heparin Thrombosis research ;; Kijowski R, Hoppensteadt D, Jeske W, Fareed J. Protamine sulfate neutralization of the anticoagulant activity of Aprosulate, a synthetic sulfated lactobionic acid amide Thrombosis research ;; Kowal-Vern A, Walenga JM, Hoppensteadt D, Sharp-Pucci M, Gamelli RL. Interleukin-2 and interleukin-6 in relation to burn wound size in the acute phase of thermal injury Journal of the American College of Surgeons ;; Kaiser B, Jeske W, Hoppensteadt D, Fareed J. Inhibitory effects of TFPI variants on thrombin and factor Xa generation in fibrinogen-deficient human plasma Thrombosis research ;; Kaiser B, Hoppensteadt DA, Jeske W, Wun TC, Fareed J. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro--modulatory action of glycosaminoglycans Thrombosis research ;; Callas D, Bacher P, Iqbal O, Hoppensteadt D, Fareed J. Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin Thrombosis research ;; Fareed J, Hoppensteadt D, Walenga JM, Bick RL. Current trends in the development of anticoagulant and antithrombotic drugs MEDICAL CLINICS OF NORTH AMERICA ;; Kaiser B, Callas D, Hoppensteadt D, Mallinowska K, Fareed J. Comparative studies on the inhibitory spectrum of recombinant hirudin, DuP 714 and heparin on thrombin and factor Xa generation in biochemically defined systems Thrombosis research ;; Bacher P, Horst B, Breyer HG, Hoppensteadt DA, Walenga JM, Fareed J. Postoperative monitoring of low molecular weight heparin prophylaxis in high-risk patients Seminars in Thrombosis and Hemostasis ;; Hoppensteadt D, Jeske W, Fareed J. Pharmacological profile of reviparin-sodium Blood Coagulation & Fibrinolysis ;; Hoppensteadt DA, Haas S, Breddin HK, Fareed J. Modulation of laboratory parameters after therapeutic and prophylactic administration of Sandoparin Seminars in Thrombosis and Hemostasis ;; Malinowska K, Iqbal O, Hoppensteadt DA, Walenga JM, Fareed J. In vivo study of bleeding and antithrombotic effects of low molecular weight heparin ML-009723 Seminars in Thrombosis and Hemostasis ;; Lojewski B, Bacher P, Iqbal O, Walenga JM, Hoppensteadt DA, Leya F, Fareed J. Evaluation of hematologic alterations associated with daily administration of low molecular weight heparin (Mono-Embolex) for a 12-week period Seminars in Thrombosis and Hemostasis ;; Fareed J, Hoppensteadt DA, Walenga JM. Current perspectives on low molecular weight heparins Seminars in Thrombosis and Hemostasis ;; Callas DD, Hoppensteadt DA, Jeske W, Iqbal O, Bacher P, Ahsan A, Fareed J. Comparative pharmacologic profile of a glycosaminoglycan mixture, Sulodexide, and a chemically modified heparin derivative, Suleparoide Seminars in Thrombosis and Hemostasis ;; Jeske W, Lojewski B, Walenga JM, Hoppensteadt D, Ahsan A, Fareed J. Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin) Seminars in Thrombosis and Hemostasis ;; Iqbal O, Jeske W, Bacher P, Hoppensteadt DA, Walenga JM, Fareed J. A comparison of the pharmacokinetic and pharmacodynamic profiles of Clexane and Lovenox in dogs Seminars in Thrombosis and Hemostasis ;; Bacher P, Welzel D, Iqbal O, Hoppensteadt D, Callas D, Walenga JM, Fareed J. The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model Thrombosis research ;; Kowal-Vern A, Gamelli RL, Walenga JM, Hoppensteadt D, Sharp-Pucci M, Schumacher HR. The effect of burn wound size on hemostasis: a correlation of the hemostatic changes to the clinical state Journal of Trauma & Acute Care Surgery ;; Fareed J, Bacher P, Messmore HL, Walenga JM, Hoppensteadt DA, Strano A, Pifarre R. Pharmacological modulation of fibrinolysis by antithrombotic and cardiovascular drugs PROGRESS IN CARDIOVASCULAR DISEASES ;; Hoppensteadt D, Walenga JM, Fareed J. Low molecular weight heparins. An objective overview DRUGS & AGING ;; Walenga JM, Hoppensteadt D, Fareed J, Pifarr? R. Hemostatic abnormalities in total artificial heart patients as detected by specific blood markers Annals of Thoracic Surgery ;; Fareed J, Walenga JM, Leya F, Bacher P, Hoppensteadt D, Messmore H, Pifarre R. Some objective considerations for the use of heparins and recombinant hirudin in percutaneous transluminal coronary angioplasty Seminars in Thrombosis and Hemostasis ;; Fareed J, Walenga JM, Pifarre R, Hoppensteadt D, Koza M. Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin Journal of Thrombosis and Haemostasis ;; Hoppensteadt D, Walenga JM, Fareed J. Protamine sulfate neutralization of lactobionic acid amides Seminars in Thrombosis and Hemostasis ;; Fareed J, Coker S, Iqbal O, Hoppensteadt D, Walenga JM. Pharmacodynamics of a sulfated lactobionic acid amide-derived antithrombotic agent (Aprosulate) in primates Seminars in Thrombosis and Hemostasis ;; Walenga JM, Hoppensteadt D, Fareed J. Non-heparin glycosaminoglycan-derived drugs: a biochemical and pharmacologic perspective Seminars in Thrombosis and Hemostasis ;; Fareed J, Walenga JM, Hoppensteadt D, Iyer L, Pifarre R. Neutralization of recombinant hirudin: some practical considerations Seminars in Thrombosis and Hemostasis ;; Fareed J, Hoppensteadt D, Walenga JM, Ahsan A, Coyne E, Breddin HK. Molecular and functional heterogeneity in dermatan sulfate preparations Seminars in Thrombosis and Hemostasis ;; Walenga JM, Hoppensteadt D, Fareed J. Laboratory monitoring of the clinical effects of low molecular weight heparins Thrombosis research ;; Walenga JM, Hoppensteadt D, Koza M, Wallock M, Pifarre R, Fareed J. Laboratory assays for the evaluation of recombinant hirudin Journal of Thrombosis and Haemostasis ;; Fareed J, Walenga JM, Hoppensteadt D, Borris LC, Lassen MR. Experimental and clinical validation of the prophylactic antithrombotic effects of a low molecular weight heparin (enoxaparin) Seminars in Thrombosis and Hemostasis ;; Hoppensteadt DA, Walenga JM, Fareed J. Effect of dermatan sulfate and heparan sulfate on platelet activity compared to heparin Seminars in Thrombosis and Hemostasis ;; Walenga JM, Hoppensteadt D, Koza M, Pifarre R, Fareed J. Comparative studies on various assays for the laboratory evaluation of r-hirudin Seminars in Thrombosis and Hemostasis ;; Fareed J, Walenga JM, Iyer L, Hoppensteadt D, Pifarre R. An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent Blood Coagulation & Fibrinolysis ;; Fareed J, Walenga JM, Lassen M, Borris L, Hoppensteadt D, Murphy R, Ahsan A, Weber S, Jorgensen LN, Hauch O, et al. Pharmacologic profile of a low molecular weight heparin (enoxaparin): experimental and clinical validation of the prophylactic antithrombotic effects Acta chirurgica Scandinavica Supplementum ;; Reddy VB, Kowal-Vern A, Hoppensteadt DA, Kumar A, Walenga JM, Fareed J, Schumacher HR. Global and molecular hemostatic markers in acute myeloid leukemia American Journal of Clinical Pathology ;; Hoppensteadt D, Walenga JM, Fareed J. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin Thrombosis research ;; Racanelli A, Hoppensteadt DA, Fareed J. In vitro protamine neutralization profiles of heparins differing in source and molecular weight Seminars in Thrombosis and Hemostasis ;; Walenga JM, Pifarre R, Hoppensteadt DA, Fareed J. Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerations Seminars in Thrombosis and Hemostasis ;; Hoppensteadt D, Racanelli A, Walenga JM, Fareed J. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparin Seminars in Thrombosis and Hemostasis ;; Fareed J, Walenga JM, Hoppensteadt D, Racanelli A, Coyne E. Chemical and biological heterogeneity in low molecular weight heparins: implications for clinical use and standardization Seminars in Thrombosis and Hemostasis ;; Fareed J, Walenga JM, Hoppensteadt D, Huan X, Nonn R. Biochemical and pharmacologic inequivalence of low molecular weight heparins Annals of the New York Academy of Sciences ;; Fareed J, Walenga JM, Racanelli A, Hoppensteadt D, Huan X, Messmore HL. Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins Journal of Thrombosis and Haemostasis ;; Fareed J, Walenga JM, Hoppensteadt DA, Kumar A, Ulutin ON, Cornelli U. Pharmacologic profiling of defibrotide in experimental models Seminars in Thrombosis and Hemostasis ;; Fareed J, Walenga JM, Hoppensteadt D, Huan X, Racanelli A. Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins Journal of Thrombosis and Haemostasis ;